# Integral Molecular

> A research\-driven biotechnology company offering innovative solutions for advancing therapies against difficult\-to\-treat diseases\.

Generated by Yoast SEO v27.6, this is an llms.txt file, meant for consumption by LLMs.

## Pages
- [About Us](https://intg.wpenginepowered.com/about-us/)
- [Contact](https://intg.wpenginepowered.com/contact/)
- [Legal Information](https://intg.wpenginepowered.com/legal-information/)
- [Privacy Policy](https://intg.wpenginepowered.com/privacy-policy/)
- [Membrane Proteome Array](https://intg.wpenginepowered.com/membrane-proteome-array/)
- [Lipoparticles](https://intg.wpenginepowered.com/lipoparticles/)
- [MPS Antibody Discovery](https://intg.wpenginepowered.com/mps-antibody-discovery/)
- [Epitope Mapping](https://intg.wpenginepowered.com/epitope-mapping/)
- [Paratope\-PLUS CDR\-Scanning](https://intg.wpenginepowered.com/paratope-plus/)
- [Virology Products \& Services](https://virology.integralmolecular.com/)
- [Therapeutic Pipeline](https://intg.wpenginepowered.com/therapeutic-pipeline/)
- [News \& Events](https://intg.wpenginepowered.com/company/news/)
- [Resources](https://intg.wpenginepowered.com/resources/)
- [Quality](https://intg.wpenginepowered.com/quality/)
- [Specificity Insights Blog](https://intg.wpenginepowered.com/membrane-proteome-array/specificity-insights/)

## Posts
- [The Consequences of Off\-Target Binding Are Real\. So Are the Solutions\.](https://intg.wpenginepowered.com/the-consequences-of-off-target-binding-are-real-so-are-the-solutions/): Off\-target binding doesn't always cause harm—but when it goes undetected, the consequences can be serious\. Published case studies document off\-target interactions that caused adverse events in clinical trials, halted drug development programs, and may explain the known safety profiles of approved therapeutics\.
- [Webinar Presented by Integral Molecular and The Antibody Society \- 100\+ Undruggable Targets Unlocked Through Parallel MAb Engineering](https://intg.wpenginepowered.com/webinar-presented-by-integral-molecular-and-antibody-society-100-undruggable-targets-unlocked-through-parallel-mab-engineering/)
- [1 in 3 Antibody Drug Candidates Bind Off\-Targets\. Here’s What That Means\.](https://intg.wpenginepowered.com/1-in-3-antibody-drug-candidates/)
- [How Is the MPA Being Qualified by the FDA?](https://intg.wpenginepowered.com/how-is-the-mpa-being-qualified-by-the-fda/): In 2021, we began working with the FDA to qualify the MPA as a Drug Development Tool through the ISTAND program\. While the FDA already accepts MPA data, this qualification process validates the scientific rigor behind the platform and helps formalize the shift toward more predictive, human\-relevant specificity testing methods\.
- [Are Tissue Cross\-Reactivity Studies Sufficient for Biotherapeutic Specificity Testing?](https://intg.wpenginepowered.com/are-tissue-cross-reactivity-studies-sufficient-for-biotherapeutic-specificity-testing/): Even though TCR is widely used and has long been recommended by the FDA, it has a long and much\-discussed list of limitations\. There is a clear need for a shift to newer specificity testing approaches that are quantitative, objective, validated, and better correlated with patient safety outcomes\.

## Mega Menu Items
- [elementor\-mega\-item\-77](https://intg.wpenginepowered.com/jet-menu/elementor-mega-item-77/)
- [default\-mega\-item\-16210](https://intg.wpenginepowered.com/jet-menu/default-mega-item-16210/)
- [elementor\-mega\-item\-26347](https://intg.wpenginepowered.com/jet-menu/elementor-mega-item-26347/)
- [elementor\-mega\-item\-78](https://intg.wpenginepowered.com/jet-menu/elementor-mega-item-78/)
- [mega\-item\-986](https://intg.wpenginepowered.com/jet-menu/mega-item-986/)

## Landing Pages
- [Download Banik et al 2025 Nature Biotech Paper](https://intg.wpenginepowered.com/download-banik-et-al-2025/)
- [Annotated Patent Download Page](https://intg.wpenginepowered.com/annotated-patent-download/)
- [Elementor Landing Page \#20179](https://intg.wpenginepowered.com/elementor-landing-page-20179/)

## SARS\-CoV\-2 RVP Docs
- [Lot HNL\-751A](https://intg.wpenginepowered.com/sars_cov_2_rvp_docs/lot-hnl-751a/)
- [Lot HNG\-750A](https://intg.wpenginepowered.com/sars_cov_2_rvp_docs/lot-hng-750a/)
- [T03 Neutralization of HIV GFP RVPs](https://intg.wpenginepowered.com/sars_cov_2_rvp_docs/t03-neutralization-of-hiv-gfp-rvps/)
- [T02 Infectivity of HIV GFP RVPs](https://intg.wpenginepowered.com/sars_cov_2_rvp_docs/t02-infectivity-of-hiv-gfp-rvps/)
- [HIV RVP SDS](https://intg.wpenginepowered.com/sars_cov_2_rvp_docs/hiv-rvp-sds/)

## Categories
- [News](https://intg.wpenginepowered.com/category/news/)
- [Publications](https://intg.wpenginepowered.com/category/publications/)
- [Virology](https://intg.wpenginepowered.com/category/publications/virology/)
- [Mapping and Engineering](https://intg.wpenginepowered.com/category/publications/mapping-and-engineering/)
- [Uncategorized](https://intg.wpenginepowered.com/category/uncategorized/)

## Optional
- [Sitemap index](https://intg.wpenginepowered.com/sitemap_index.xml)